Kymera Therapeutics (KYMR) is back in focus after showcasing expanded Phase 1b data for KT-621, its oral STAT6 degrader, at major dermatology and respiratory conferences. The company highlighted clinical signals in atopic dermatitis and asthma.

Despite the recent KT-621 data spotlight, Kymera Therapeutics’ share price has eased in the near term, with the 30 day share price return down 7.09% and the 90 day share price return down 10.79%. At the same time, the 1 year total shareholder return of 167.51% points to strong earlier momentum that has cooled recently.

If progress on KT-621 has you looking at other potential growth stories in healthcare, it could be a good moment to scan a wider field of 34 healthcare AI stocks.

With Kymera shares easing recently after a strong 1 year run, yet trading at a sizable discount to the average analyst price target, investors face a key question: is there still upside potential here or has the market already priced in future growth?

Most Popular Narrative: 33.6% Undervalued

Kymera Therapeutics' most followed narrative pegs fair value at $118.86 per share versus the last close at $78.89, framing a sizeable valuation gap and putting the oral degrader story under the microscope.

The collaboration with Sanofi on the IRAK4 program, with expanded Phase II trials, positions Kymera to fast-track toward pivotal trials, potentially accelerating time-to-market and impacting future earnings positively.

The company's strategy to introduce at least one new IND per year could expand their pipeline steadily, offering opportunities for revenue growth from licensing deals or partnerships.

Want to see what kind of revenue curve and margin profile analysts think could justify that fair value gap? The narrative leans on rapid top line expansion, a sharp shift in profitability, and a future earnings multiple that would usually be reserved for standout growth stories.

Result: Fair Value of $118.86 (UNDERVALUED)

However, the story can change quickly if high R&D spending fails to translate into successful commercialization, or if partner setbacks slow progress in key degrader programs.

Next Steps

Curious whether the mix of excitement and caution here really adds up for you? Take a closer look now and weigh both sides by checking out the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Kymera has sharpened your interest in stock picking, do not stop here. Use the screener to uncover fresh ideas that could reshape your portfolio.

• Target steady cash generators by scanning companies with reliable payouts using the 10 dividend fortresses.
• Spot potential bargains before they are crowded by reviewing the screener containing 21 high quality undiscovered gems.
• Prioritize resilience and sleep easier at night by focusing on the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.